LabCorp 2014 Annual Report Download - page 16

14
and screening tests, profiles for reproductive health, factor analysis, thrombin generation markers, and thrombotic risk
evaluation.
Diagnostic Genetics. The Company offers cytogenetic, molecular cytogenetic, biochemical and molecular genetic tests.
The biochemical genetics offerings include a variety of prenatal screening options including integrated and sequential prenatal
assays and non-invasive prenatal testing for more sensitive assessment of Down Syndrome risk. The Company has expanded
its cytogenetics offerings through the use of whole genome single-nucleotide polymorphism ("SNP") microarray technology,
which provides enhanced detection of subtle chromosomal changes associated with the etiology of mental retardation,
developmental delay and autism. The molecular genetics services include multiplex analyses of a variety of disorders, gene
sequencing applications for both somatic and germ-line alterations and whole exome sequencing. Through Integrated
Genetics, the Company provides the most comprehensive genetic test menu in the industry as well as approximately 140
genetic counselors and 6 medical geneticists to work with the Company's physician clients in optimizing patient outcomes.
Endocrinology. The Company has emerged as a leading provider of advanced hormone/steroid testing including
comprehensive services for the endocrine specialist. The Company has expanded its menu in esoteric endocrine testing and
has launched a companywide initiative to develop steroid testing utilizing mass spectrometry technology. Mass spectrometry
is quickly becoming the gold standard for detection of low levels of small molecule steroids including testosterone in women,
children and hypogonadal men. The Company additionally offers several endocrine related genetic tests that include CYP21
mutation for congenital adrenal hyperplasia, SHOX gene for short stature, RET mutation for thyroid cancer as well as
extensive age and gender-related reference intervals.
Infectious Disease. The Company provides complete HIV testing services including viral load measurements, genotyping
and phenotyping and host genetic factors (e.g., HLA B*5701 test) that are important tools in managing and treating HIV
infections. The addition of resistance tests, PhenoSense®, PhenoSenseGT®, Trofile®, and GenoSure PRImeSM complement
the existing HIV GenoSure® assay and provide an industry-leading, comprehensive portfolio of HIV resistance testing
services. The Company also provides extensive testing services for HCV infections, including both viral load determinations
and strain genotyping and host genetic factors (e.g. IL-28B test and HCV GenoSure® NS3/4A). The Company continues to
develop molecular assays for infectious disease.
Obstetrics/Gynecology. The Company offers a comprehensive menu of women's health testing, including NuSwab® high
quality convenient STD testing, as well as liquid-based Pap testing with image-guided cervical cytology for improved cervical
cancer detection, and out-of-the-vial Pap testing with options for HPV, Chlamydia, and gonorrhea. The Company also offers
tests and technologies that span the continuum of care for reproductive health, including maternal serum screening, prenatal
diagnostics, ethnicity carrier screening, testing for causes of infertility or miscarriage and postnatal testing services.
Pharmacogenetics. The Company provides access to the latest tests in the emerging field of pharmacogenetics. These tests
can help physicians understand how a patient will metabolize certain drugs, allowing them to recommend the most appropriate
therapies or adjust dosing.
Clinical Trials. The Company regularly performs clinical laboratory testing for pharmaceutical and diagnostics companies
conducting clinical research trials on new drugs or diagnostic assays. This testing often involves periodic testing of patients
participating in the trial over several years. In 2011, the Company acquired Clearstone Central Laboratories, a global central
laboratory specializing in drug development and pharmaceutical services.
Identity. The Company provides forensic identity testing used in connection with criminal proceedings and parentage
evaluation services which are used to assist in determining parentage for child support enforcement proceedings and
determining genetic relationships for immigration purposes. Parentage testing involves the evaluation of immunological and
genetic markers in specimens obtained from the child, the mother and the alleged father. The Company also provides testing
services in reconstruction cases, which assist in determining parentage without the presence of the parent in question.
Occupational Testing Services. The Company provides testing services for the detection of drug and alcohol abuse for
private and government customers. These testing services are designed to produce forensic quality test results that satisfy
the rigorous requirements for admissibility as evidence in legal proceedings. The Company also provides other analytical
testing and a variety of support services.
Chronic Disease Programs. The Company has leveraged Litholink®'s programmatic approach to the comprehensive
treatment of chronic diseases, including kidney disease, cardiovascular disease, metabolic bone disease and diabetes and
offers these Clinical Decision Support reports to both physicians and patients. The Company believes these chronic disease